Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms B7-H4 x CD3 bi-specific mAb(Pfizer), B7-H4, PF 07260437 + [1] |
Target |
Mechanism B7-H4 modulators(V-set domain-containing T-cell activation inhibitor 1 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 07 Oct 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | PR | 07 Oct 2021 | |
Endometrial Carcinoma | Phase 1 | US | 07 Oct 2021 | |
Endometrial Carcinoma | Phase 1 | PR | 07 Oct 2021 | |
Metastatic breast cancer | Phase 1 | US | 07 Oct 2021 | |
Metastatic breast cancer | Phase 1 | PR | 07 Oct 2021 | |
Ovarian Cancer | Phase 1 | US | 07 Oct 2021 | |
Ovarian Cancer | Phase 1 | PR | 07 Oct 2021 |